Wall Street Apostles Find Salvation In St. Jude During 2Q; Stock Is Up 78%
This article was originally published in The Gray Sheet
Executive Summary
A continued strong performance by St. Jude Medical's Cardiac Rhythm Management business combined with the expectation of key regulatory approvals by year-end sparked a 77.7% run-up in the company's stock during the second quarter of 2000.
You may also be interested in...
St. Jude Tempo, Meta Pacer Advisory Calls For Replacement In Some Patients
"Significantly pacemaker-dependent" individuals implanted with certain Tempo and Meta pacemakers should have the devices replaced given the "potential for loss of pacing function," St. Jude Medical recommends in a June 7 physician advisory.
Staar Surgical Toric, Allergan Array Given HCFA "New Technology" Status
Staar Surgical's Toric and Allergan's Array intraocular lenses were awarded "new technology" status by the Health Care Financing Administration, according to a May 3 Federal Register notice, while four other IOLs were denied their bid for higher reimbursement.
St. Jude Cardiovascular Access Sales Jump 107% In Q1 To $23 Mil.
Strong U.S. sales of the 6 Fr version of St. Jude Medical's Angio-Seal hemostatic puncture closure system since its introduction in mid-March, and "the expansion and focus of cardiology vascular access selling efforts in the U.S.," were the driving forces behind a 107% jump in first quarter cardiovascular access product sales to $23 mil.